In short
Diagnosing metastatic pancreatic neuroendocrine tumors requires a combination of imaging studies, blood tests, and tissue analysis. Because these tumors can behave very differently from the more common types of pancreatic cancer, accurate diagnosis is essential for planning the right treatment approach and understanding what to expect in the months and years ahead.
Key points
- Pancreatic neuroendocrine tumors grow much more slowly than the common type of pancreatic cancer, allowing many patients to live for years even with metastatic disease.
- Many of these tumors are discovered accidentally during imaging tests for unrelated conditions because they may not cause symptoms until they are quite large.
- Blood and urine tests can detect excess hormones produced by functional tumors, helping doctors identify the specific type of tumor and plan treatment.
- The Ki67 proliferation index, measured from a biopsy, is a key factor in determining how aggressive the tumor is and what treatments might work best.
- Well-differentiated, low-grade tumors have a much better outlook than poorly differentiated, high-grade tumors, and can often be managed for many years.
- Clinical trials require specific diagnostic tests to confirm tumor type, grade, and extent of disease, and maintaining up-to-date medical records can help you access new treatments.
- The five-year survival rate for metastatic pancreatic neuroendocrine tumors is significantly higher than for other types of pancreatic cancer, especially with modern treatments.
- Even with liver metastases, many patients can achieve long periods of disease control with targeted therapies, hormone treatments, or liver-directed procedures.
Introduction: When to Seek Diagnostic Testing
Not everyone with a pancreatic neuroendocrine tumor will experience symptoms right away. In fact, many people discover they have this condition during imaging tests performed for completely unrelated reasons. However, certain warning signs should prompt you to see a healthcare professional for further evaluation.
You should consider seeking medical attention if you experience persistent symptoms that don't improve over time. These may include ongoing stomach pain, unexplained weight loss, frequent diarrhea, or unusual fatigue that interferes with your daily activities. Some people notice yellowing of their skin or the whites of their eyes, which is called jaundice. Others experience repeated episodes of heartburn, muscle cramps, or digestive problems that seem unusual or more severe than before.
Because pancreatic neuroendocrine tumors grow slowly compared to other pancreatic cancers, symptoms may develop gradually over months or even years. Some tumors produce hormones that cause specific symptoms, such as low blood sugar, severe stomach ulcers, or skin rashes. These hormone-related symptoms can sometimes lead to an earlier diagnosis because they are more noticeable and troubling to patients.
Many nonfunctional tumors, which do not produce excess hormones, remain silent until they grow large enough to press on nearby organs or spread to the liver. This is why these tumors are often diagnosed at a more advanced stage. If you have a family history of certain genetic conditions, such as Multiple Endocrine Neoplasia Type 1, you may be at higher risk and should discuss regular monitoring with your doctor.
Classic Diagnostic Methods
Once you and your doctor suspect a pancreatic neuroendocrine tumor, a series of tests will help confirm the diagnosis and determine the extent of the disease. The diagnostic process typically begins with blood and urine tests, followed by imaging studies and, in most cases, a tissue biopsy to examine the tumor cells under a microscope.
Blood and Urine Tests
Blood tests can reveal important clues about the presence of a pancreatic neuroendocrine tumor. If the tumor is functional, meaning it produces hormones, blood tests can detect elevated levels of these hormones. For example, high levels of gastrin may suggest a gastrinoma, while increased insulin levels might indicate an insulinoma. Your doctor may also check for elevated levels of chromogranin A, a protein that is often higher in people with neuroendocrine tumors.
Urine tests can also be helpful. They may show breakdown products of hormones that your body has processed. These tests are particularly useful for identifying certain functional tumors that release hormones into the bloodstream. Together, blood and urine tests help doctors understand what type of tumor you might have and whether it is producing substances that could affect your health.
Imaging Tests
Imaging studies are essential for seeing the tumor and understanding where it is located, how large it is, and whether it has spread to other parts of the body. Several types of imaging tests are commonly used in the diagnosis of metastatic pancreatic neuroendocrine tumors.
Computed tomography (CT) scans use X-rays to create detailed cross-sectional images of the abdomen. A CT scan can show the pancreas, liver, and other organs, helping doctors identify tumors and metastases. This test is often one of the first imaging studies performed when a pancreatic tumor is suspected.
Magnetic resonance imaging (MRI) uses magnetic fields and radio waves to produce highly detailed images of soft tissues. MRI is particularly useful for examining the liver, where metastatic pancreatic neuroendocrine tumors often spread. It can distinguish between benign cysts and cancerous lesions, providing valuable information for treatment planning.
Nuclear medicine scans, such as positron emission tomography (PET) scans combined with CT or MRI, involve injecting a small amount of radioactive tracer into your body. The tracer attaches to neuroendocrine tumor cells, making them visible on the images. This type of scan is especially helpful for finding small tumors or metastases that might not show up on other imaging tests.
Some patients undergo specialized scans that use tracers specifically designed to bind to neuroendocrine tumors. These scans can provide even more precise information about the location and extent of the disease, helping doctors plan the most appropriate treatment.
Endoscopic Ultrasound and Tissue Biopsy
An endoscopic ultrasound is a procedure in which a thin, flexible tube with a camera and ultrasound device on the tip is passed down your throat and into your stomach and small intestine. This allows the doctor to get very close to the pancreas and create detailed images from inside your body. The ultrasound can show the size and characteristics of the tumor more clearly than external imaging.
During the endoscopic ultrasound, the doctor can also use special tools to collect a small sample of tissue from the tumor. This is called a biopsy. The tissue sample is then sent to a laboratory where a specialist examines the cells under a microscope. This examination, known as histopathology, confirms whether the tumor is a neuroendocrine tumor and provides information about how fast the cells are dividing.
In some cases, a liver biopsy may be performed if metastases are present in the liver. The biopsy helps confirm that the liver lesions are related to the pancreatic tumor and not from another source. Knowing the characteristics of the tumor cells, including their growth rate, is crucial for determining the best treatment approach.
Tumor Grading and Differentiation
Once a biopsy is obtained, the tumor is examined for its grade and differentiation. The grade refers to how abnormal the tumor cells look under the microscope and how quickly they are dividing. A key marker used in grading is the Ki67 proliferation index, which measures the percentage of cells that are actively dividing. Tumors with a low Ki67 index (less than 3 percent) are considered low grade and tend to grow slowly. Tumors with a higher Ki67 index are intermediate or high grade and may grow more aggressively.
Differentiation describes how much the tumor cells resemble normal pancreatic cells. Well-differentiated tumors look more like normal cells and typically grow more slowly. Poorly differentiated tumors look very abnormal and tend to grow and spread more quickly. Well-differentiated tumors generally have a better outlook than poorly differentiated ones.
Understanding the grade and differentiation of your tumor helps doctors predict how the disease is likely to behave and choose the most appropriate treatments. For example, low-grade, well-differentiated tumors may be managed with different strategies than high-grade, poorly differentiated tumors.
Diagnostics for Clinical Trial Qualification
Clinical trials are research studies that test new treatments or combinations of treatments to see if they are safe and effective. Participating in a clinical trial can give you access to the latest therapies that are not yet widely available. However, entering a clinical trial requires meeting specific criteria, and diagnostic tests play a central role in determining whether you are eligible.
Confirming Tumor Type and Grade
Clinical trials for metastatic pancreatic neuroendocrine tumors often require confirmation that you have a well-differentiated neuroendocrine tumor with a specific grade. This means you will need a biopsy and histopathology report that clearly identifies the tumor as a pancreatic neuroendocrine tumor and provides information about the Ki67 proliferation index. Trials may accept only low-grade or intermediate-grade tumors, or they may focus on more aggressive, high-grade tumors.
Some trials also require genetic testing or biomarker analysis to identify specific mutations or characteristics in the tumor cells. Biomarkers are substances in the blood or tissue that can indicate the presence of disease or predict how the disease will respond to treatment. Testing for biomarkers can help match you to a trial that targets the specific features of your tumor.
Imaging and Disease Staging
Clinical trials often require recent imaging studies to confirm the extent of the disease. This is called staging. Staging describes whether the tumor is confined to the pancreas, has spread to nearby lymph nodes, or has metastasized to distant organs such as the liver or bones. Most trials for metastatic disease require evidence of metastases on imaging.
You may need to undergo additional imaging tests, such as a PET scan or specialized nuclear medicine scan, as part of the screening process for a clinical trial. These tests provide detailed information about the location and activity of the tumor and metastases. The imaging must typically be done within a certain time frame before enrollment, such as within four weeks, to ensure the information is current.
Functional Status and Performance Score
Clinical trials also assess your overall health and ability to carry out daily activities. This is measured using a performance status score, such as the Eastern Cooperative Oncology Group (ECOG) scale. A performance status of 0 means you are fully active, while higher scores indicate increasing limitations. Most trials require a performance status of 0 or 1, meaning you are able to function relatively normally despite your illness.
Your doctors will evaluate your ability to tolerate the treatments being tested in the trial. This may involve additional blood tests to check your liver and kidney function, blood counts, and other measures of overall health. These tests help ensure that the trial treatment will be safe for you and that you are likely to benefit from it.
Prior Treatment History
Some clinical trials are designed for patients who have already received certain treatments, such as chemotherapy or targeted therapy. In these cases, the trial may require documentation of your previous treatments and evidence that your disease has progressed despite those treatments. This is often determined through repeat imaging studies that show new tumor growth or spread.
Other trials may be open to patients who have not yet received any treatment for metastatic disease. These are often called first-line trials. The eligibility criteria for these trials may be less restrictive in terms of prior treatment history, but they still require thorough diagnostic testing to confirm the diagnosis and stage of the disease.
Prognosis and Survival Rate
Prognosis
The outlook for patients with metastatic pancreatic neuroendocrine tumors varies widely depending on several factors. Unlike the more common type of pancreatic cancer called adenocarcinoma, which tends to grow and spread quickly, pancreatic neuroendocrine tumors often grow more slowly and can be managed for many years even when they have spread to other organs.
The grade and differentiation of the tumor play a major role in determining prognosis. Low-grade, well-differentiated tumors tend to grow slowly and respond better to treatment. Patients with these tumors may live for many years with the disease, especially if it can be controlled with medication or surgery. Intermediate-grade tumors have a slightly worse prognosis but can still be managed effectively with a combination of therapies. High-grade, poorly differentiated tumors are more aggressive and may require more intensive treatment approaches.
The extent of the disease at diagnosis also affects prognosis. Tumors that are confined to the pancreas and can be surgically removed have a better outlook than those that have spread to the liver or other organs. However, even with metastatic disease, many patients can achieve long periods of disease control with appropriate treatment. The presence of metastases in the liver is common, but liver-directed therapies and systemic treatments can help slow disease progression and relieve symptoms.
Other factors that influence prognosis include your overall health, how well your body tolerates treatment, and how the tumor responds to therapy. Functional tumors that produce hormones may cause troubling symptoms, but they can often be managed with medications that block hormone production. Nonfunctional tumors may be discovered at a more advanced stage, but they often grow more slowly than other cancers.
Survival rate
Survival rates for metastatic pancreatic neuroendocrine tumors are generally more favorable than for other types of pancreatic cancer. According to available data, the five-year relative survival rate for patients with localized pancreatic neuroendocrine tumors that have not spread is approximately 95 percent. For tumors that have spread to distant organs, the five-year relative survival rate is around 23 percent.
It is important to understand that survival statistics are based on large groups of patients and cannot predict exactly what will happen to any individual person. These numbers reflect outcomes from patients diagnosed and treated in the past, and newer treatments continue to improve survival rates. Many patients with metastatic disease live much longer than the statistics suggest, especially if they respond well to treatment and are able to maintain a good quality of life.
In clinical studies, patients with well-differentiated metastatic pancreatic neuroendocrine tumors treated with targeted therapies, hormone therapy, or liver-directed treatments have achieved median progression-free survival times ranging from several months to over a year. Progression-free survival refers to the time during which the disease does not get worse. Some patients experience stable disease for many years, allowing them to continue their normal activities and maintain their quality of life.
The case of a 62-year-old man with metastatic pancreatic neuroendocrine tumor, who received multiple lines of chemotherapy, hormone therapy, and radiotherapy, illustrates both the challenges and the potential for extended survival. Despite progressive disease and metastases to the liver, spleen, and bones, he lived for over two years following his diagnosis. This highlights that even in advanced cases, treatment can provide meaningful time and symptom control.
